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Abstract
We have attempted to use a familial genetics strategy to study mechanisms of Topoisomerase 1
(Top1) inhibition. Investigations have steadily been chipping away at the pathways involved in
cellular response following Top1 inhibition for more than 20 years. Our system-wide approach,
which phenotypes a collection of genotyped human cell lines for sensitivity to compounds,
interrogates all genes and molecular pathways simultaneously. Previously, we characterized the in
vitro sensitivity of fifteen families of CEPH cell lines (n = 142) to nine camptothecin analogues.
Linkage analysis revealed a pattern of seven quantitative trait loci (QTLs) shared by all of the
camptothecins. To identify which, if any, QTLs are related to the general mechanism of Top1
inhibition or should be considered camptothecin-specific, we characterized the in vitro sensitivity
of the same panel of CEPH cell lines to the indenisoquinolones, a structurally distinct class of Top
1 inhibitors. Four QTLs on chromosomes 1, 5, 11, and 16 were shared by both the camptothecins
and the indenoisoquinolines and are considered associated with the general mechanism of Top1
inhibition. The remaining three QTLs (chromosomes 6 and 20) are considered specific to
camptothecin-induced cytotoxicity. Finally, eight QTLs were identified which were unique to the
indenoisoquinolines.
INTRODUCTION
Since the discovery of Topoisomerase 1 (Top1) as a therapeutic target for the treatment of
cancer, the design of Top1 inhibitors has been actively pursued. The camptothecins are the
only Top1 inhibitors approved for clinical use by the Food and Compound Administration.
In spite of activity in colon, lung, and ovarian cancers, their efficacy is compromised by a
number of factors (1). The camptothecins are unstable and rapidly inactivated by ring
opening of their lactone functionality at physiologic pH. Top1 cleavage complexes (Top1cc)
reverse within minutes after compound withdrawal and require frequent and prolonged
exposure (2, 3). Side effects are concentration-limiting and at times severe. These drawbacks
prompted the search for additional novel Top1 inhibitors. The indenoisoquinolines (Ind) are
one of the many non-camptothecin Top1 inhibitors in development. Their antiproliferative
activity is comparable to the camptothecins in the NCI60 panel, a set of 59 human cancer
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cell lines derived from diverse tissues. However, differences in structure (4), interactions
with Top1 and DNA (3, 5) and resistance mechanisms (3, 6) suggests that these compounds
may have subtle distinctions in therapeutic activity and mechanisms of action.
Compound-to-compound comparative studies between structurally distinct compounds
sharing a molecular target have been used to identify genes and pathways which are
involved in a shared general mechanism and those which are class-specific (7, 8). Our own
familial genetics strategy is one of the latest genomic tools for dissecting mechanisms of
compound action and comparing genomic profiles across compound classes (Peters, EJ;
Motsinger-Reif, A; Havener, TM; Everitt, L; Hardison, NE; Watson, VG; Richards, K;
Province, MA; McLeod, HL. Pharmacogenetic dissection of FDA-approved cytotoxic drugs.
Submitted. and (9)). In this model, genes influencing compound action are studied using the
Centre d’Etude Polymorphisme Humain (CEPH) cell lines, a collection of densely
genotyped, immortalized, human cell lines from multigenerational families. Compound-
induced cytotoxicity is measured in these lymphoblastoid cell lines (LCLs) using a cell
growth inhibition assay following treatment with increasing concentrations of compound.
Linkage analysis is then used to identify regions of the genome, referred to as quantitative
trait loci (QTLs), where genetic variation is correlated with observed variation in response.
We have recently used this model to establish a specific pattern of QTLs shared by the
camptothecins, a group of Topoisomerase 1 (Top1) inhibitors, which is indicative of their
shared mechanism of action (9). Seven QTLs were shared across multiple concentrations of
six camptothecin analogues and then independently replicated in two separate validation
experiments. The objective of this study was to determine which QTLs are specific to
camptothecin-induced cytotoxicity and which are related to the general mechanism of Top1
inhibition. The CEPH LCLs were phenotyped for sensitivity to the indenoisoquinolines and
the resulting genomic profiles compared with the camptothecins. While sharing the same
molecular target, there are notable pharmacological distinctions between the two classes (4).
By comparing the biological and genomic profiles of the indenoisoquinolines with the
camptothecins we can demonstrate that this model can establish a pattern of QTLs (a)
related to the general mechanism of Top1 inhibition, (b) specific to camptothecin-induced
cytotoxicity, and (c) associated with indenoisoquinoline activity.
MATERIALS AND METHODS
Compounds
The following panel of camptothecins was purchased from LKT Labs (St Paul, MN):
camptothecin (CPT), irinotecan (CPT11), 7-ethyl-10-hydroxycamptothecin (SN38),
topotecan (TPT), 9-aminocamptothecin (9AC) and 9-nitrocamptothecin (9NC). The
indenoisoquinolines, NSC 706744 (Ind1), NSC 725776 (Ind2) and NSC 724998 (Ind3),
were generously supplied by Drs. Stephen Frye and Jian Jin of the Center for Integrative
Chemical Biology and Compound Discovery (University of North Carolina, Chapel Hill,
NC). All compounds were dissolved in DMSO. The chemical structures for all compounds
studied are provided in Supplemental Table 1.
Cell lines
The CEPH cell lines are a set of immortalized lymphoblastoid cell lines (LCLs) collected
from normal, healthy human volunteers which can be purchased from Corriell Cell
Repositories (Camden, NJ). This collection is unique because the cell lines are established
from large multigenerational families and every individual within the families has been
genotyped, which enables investigators to perform genetics & pharmacogenomic analyses
(10-12). For the purposes of this study, all CEPH cell lines from the following family
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identification numbers were used: 35, 45, 1334, 1340, 1341, 1345, 1350, 1362, 1408, 1420,
1447, 1451, 1454, 1459, 1463 (13). In total, cytotoxicity was studied in 142 CEPH cell lines
from 15 families; the same families were used for study with the camptothecin analogues.
The cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37°C
in humidified air containing 5% CO2. No cell line authentication was performed by the
authors prior to initiating this study.
Measurements of Cell Growth Inhibition and Data Analysis
Wells in each black, clear-bottom 384 well plate (Corning, Corning, NY) contained either
1% DMSO (vehicle, 100% cell viability), 10% DMSO (100% cell death), or increasing
concentrations of compound (8 concentrations per compound diluted in 1% DMSO) using a
Tecan Evo 150 liquid handler (Tecan, San Jose, CA) and frozen at −20 C prior to
experimentation. Each plate contained four replicates of each compound-concentration
combination. On the day of experimentation, cells were plated at a density of 4000 cells/well
(45 ul) in RMPI 1640 with 10% FBS. Alamar blue was added following 72 h compound
exposure and fluorescence read at 96 h using a Tecan F200 multiwell plate reader
(excitation 535 nm, Em 595 nm). Raw fluorescence values for each set of replicates were
considered outliers if there was a ten-fold change in signal (in either directions) for a single
replicate. Growth inhibition relative to untreated controls was determined using the
manufacturer’s protocol. Final percent inhibition at each compound-concentration
combination was averaged from 4 replicates of 2 independently plated experiments (n =8
replicates). Boxplots illustrating variation in cytotoxic response across the entire CEPH
population for each compound are supplied in Supplemental Dataset 1. Boxplots illustrating
intra- and inter-family variability in response are provided in Supplemental Dataset 2. The
Pearson correlation coefficient (PCC) was used to analyze the degree of similarity between
the biological activity profiles of the two classes of Top1 inhibitors. From the boxplot results
in Supplemental Dataset 1, the concentration closest to yielding a population mean of 50%
was selected for each compound. An activity profile or fingerprint was generated using the
percent growth inhibition at this population mean GI50 across all cell lines (rather than
constructing an activity profile using GI50 data across each cell line) for each compound.
PCC was calculated using the formula:
where xi and yi are percent growth inhibition at the population mean GI50 for each
compound A and B respectively, against each cell line, and xm and ym are the population
mean values of xi and yi respectively.
Genomic Profiling and Peak Prioritization
The genotype data for each cell line were downloaded from V10 of the CEPH database
using error checked markers (14, 15). The genetic map information was downloaded from
the Marshfield database (16, 17). Error checking and nonparametric linkage analysis was
performed as previously described (16). Linkage analysis tests for cosegregation of the
phenotype of interest along with genetic markers at known locations. Phenotypes were
defined as cytotoxic response at each compound-concentration combination. There were
three indenoisoquinoline analogues and eight concentrations were investigated for each
analogue (n = 24 phenotypes). For each phenotype, nonparametric linkage (NPL) analysis
was used to construct Quantitative Trait Loci (QTL) maps by displaying the logarithm of
odds (LOD) scores across each chromosome. The LOD score is a statistical estimate of
linkage; it is the ratio of the likelihood that a chromosomal region is linked to the phenotype
of interest over the likelihood that it is not. A LOD score of three indicates 1000 to 1 odds
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that the region is linked. A complete set of QTL maps for each compound, by chromosome
can be found in Supplemental Dataset 3.
For each compound-concentration phenotype, gene-dropping permutations were conducted
using Merlin to get a distribution of LOD scores which would occur under the null
hypothesis of no linkage to the observed phenotypes. Such a permutation strategy has been
evaluated statistically (18-20) and has been used for QTL and disease gene mapping in a
wide range of human traits (21, 22). Three thousand genotype datasets were simulated for
each compound-concentration phenotype, for a total of 72,000 simulated datasets. Results
from the permutation testing were used to identify significant and suggestive linkage results.
Using the permutation distributions, LOD score thresholds for significant linkage were
defined as those LOD scores corresponding to p-values less than or equal to 0.002 (corrected
for the entire genome: 0.05/ 22 chromosomes). This significance cut-off corresponds to a
family-wise error rate of 5% for each phenotype and was used to define significant LOD
score peaks. A region was considered significant if the highest LOD score in the region was
greater than or equal to the permutation testing derived cut-offs. A complete list of LOD
score significance cut-offs and significant peaks can be found in Supplemental Files 4 & 5
respectively. In addition to defining statistically significant peaks, suggestive QTLs were
identified using the permutation distributions. LOD score cut-offs that define suggestive
peaks were determined as the minimum LOD score needed to achieve a p-value less than or
equal to 0.05 on each chromosome. Cut-offs that define suggestive linkage for each
compound and concentration combination are also listed in Supplemental Dataset 4. QTLs
observed for a compound-concentration phenotype were considered suggestive if the highest
LOD score in that region surpassed the suggestive LOD score threshold for that compound-
concentration phenotype on that chromosome. The start and end of a significant QTL region
was defined as regions with LOD scores that were above either the suggestive LOD score
threshold or peak LOD score minus one, whichever was greater. Understanding that the goal
of this study is discovery, and very exploratory, these anti-conservative cut-offs were used
for peak identification. The “significant” cut-offs are empirically derived to control the false
positive rate to 0.05 across the genome for each drug tested, but do not control for the
number of drugs tested, as each drug response phenotype was treated as an independent
hypothesis. This is mitigated however, by looking for replication across drugs for significant
peaks. The “suggestive” cut-offs are anticonservative even within a drug outcome, and even
“replicated” suggestive peaks should be interpreted as hypothesis generating as opposed to
strictly significant.
Identifying Class-Specific QTL profiles
To identify QTLs associated with the general mechanism of Top1 inhibition, the QTLs
which have previously been identified as shared by all camptothecin analogues at multiple
concentrations, were queried for replication in the indenoisoquinolines.2 A QTL was
considered shared between the camptothecins and indenoisoquinolines only if it was present
at the significant and/or suggestive level in multiple concentrations of all three
indenoisoquinolines. QTLs which were not shared between the camptothecins and
indenoisoquinolines were considered specific to camptothecin-induced cytotoxicity. Finally,
QTLs which were significant in the indenoisoquinolines and shared across multiple
concentrations of all three indenoisoquinolines were considered indenoisoquinoline-specific.
RESULTS
Variation in Biological Response Between Top1 Inhibitors
Some have argued that molecular & pharmacological distinctions between the
camptothecins and the indenoisoquinolines could result in clinical differences (4). In this
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study, EBV-transformed LCLs derived from 15 CEPH pedigrees were used to evaluate
differences in cytotoxic activity between the indenoisoquinolines and the camptothecins.
Sensitivity to the indenoisoquinolines, Ind1 (NSC70644), Ind2 (NCS725776), and Ind3
(NSC724998), were evaluated in CEPH LCLs (n = 142) using the alamar blue assay. Ind1,
Ind2, and Ind3 all showed concentration-dependent cytotoxicity (Figure 1). Considerable
interindividual variation in sensitivity to the indenoisoquinolines was also observed (Figure
1, Supplemental Dataset 2).
Typically, for each compound, a finngerprint—its differential growth inhibitory activity
against the cell lines—is compared using data for GI50, the concentration required for 50%
growth inhibition. However, concentrations were insufficient to reach below the GI50, for
30% of the cell lines exposed to each of the idenoisoquinolines. As a result, for each
compound fingerprint, we compared the percent growth inhibition at single concentration
across all cell lines (rather than GI50 across each cell line). From the boxplot results in
Supplemental Dataset 1, the concentration closest to yielding a population mean of 50% was
selected for each compound. There was a wide range of sensitivity to the camptothecins and
indenoisoquinolines at their respective population mean GI50s (Supplemental Figure 1). The
Pearson correlation coefficient (PCC) was used to analyze the correlation between
fingerprints for compounds based on percent growth inhibition at the population mean GI50.
While both the indenoisoquinolines and camptothecins act by a similar mechanism, i.e.
Top1 inhibition, a correlation matrix on percent inhibition at the population mean GI50 for
each compound suggests distinctions between the two classes. The three
indenoisoquinolines are highly correlated with each other (PCC > 0.8) and distinct from the
camptothecins (PCC < 0) (Supplemental Table 2).
QTLs associated with Top1 inhibition
The next objective was to identify which peaks might be class-specific and which might be
associated with the general mechanism of Top1 inhibition. Seven QTLs were shared among
all camptothecin analogues investigated (Table 1).2 This pattern of QTLs was compared to
the QTLs associated with indenoisoquinoline sensitivity. A peak was considered replicated
if it was found in all three indenoisoquinolines at the significant or suggestive level. Four of
the seven predefined QTLs were shared by all of the camptothecins and all of the
indenoisoquinolines. These QTLs are summarized in Table 1. Peaks on chromosomes 11
and 16 were present at the significance level in multiple concentrations of all three
indenoisoquinolines. The QTL on chromosomes 5 was significant at multiple concentrations
of Ind2 and met the suggestive threshold for multiple concentrations of all three
indenoisoquinolines. Finally, the QTL on chromosome 1 was shared by multiples
concentrations of all three indenoisoquinolines at the suggestive level only. Most notably,
the peak on chromosome 20, which contains Top1 and is shared by all of the camptothecins,
was not present at the significant level in any indenoisoquinoline. However, it was present at
the suggestive level in at least one concentration of Ind1 and Ind3. These results are
illustrated in Supplemental Figure 2, a genome wide map of QTLs at the significant and
suggestive level for both the camptothecins and indenoisoquinolines. The remaining QTLs
on chromosomes 6 and 20, which were not replicated in the indenoisoquinoline, are
considered camptothecin-specific (Table 1).
QTLs associated with indenoisoquinoline-induced cytotoxicity
There are also QTLs which appear specific to the indenoisoquinolines alone. These QTLs
are not replicated in the camptothecins and are summarized in Table 2. Of note, the QTLs on
chromosomes 6 and 16 were identified in multiple concentrations of all three
indenoisoquinolines with LOD scores that exceeded the significance thresholds (maximum
LOD score 2.286 for Ind3 at 7uM and 2.139 for 3 uM Ind2). Similarly, the QTL on
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chromosome 13 was also present in multiple concentrations of all three indenoisoquinolines
(maximum LOD score 1.44 for 10 uM Ind3). At least two indenoisoquinolines had
significant peaks on chromosomes 4 and 10 at multiple concentrations which were
replicated at the suggestive level in n ≥ 1 concentrations of the third indenoisoquinoline.
There are also subtle distinctions between the indenoisoquinolines. Multiple concentrations
of Ind1 and Ind3 had a QTL with significant LOD scores on chromosome 14 (98-134 cM);
this QTL was not present in compound-concentration combinations of Ind2. A QTL on
chromosome 19 (52-77 cM) surpasses the significance threshold for multiple concentrations
of Ind1 but is not shared by the other members of that class. Regions with significant peak
LOD scores for growth in vehicle did not overlap peaks with any of the significant QTLs
associated with sensitivity to the indenoisoquinolines (Supplemental Figure 2) with the
exception of a peak on chromosome 7 that is present in all three indenoisoquinolines. This
suggests that the remaining QTLs are associated with cytotoxicity rather than the genetic
effects from growth rate.
DISCUSSION
The similarities and differences in mechanisms between classes of compounds sharing the
same molecular target have been characterized using genomic profiling (7). In the present
study, we used pharmacologic and genomic profiling in the CEPH cell lines to investigate
two classes of Top1 inhibitors, the camptothecins and the indenoisoquinolines. Reports
indicate that while sharing the same molecular target, the indenoisoquinolines exhibit unique
properties which may set them apart clinically from the camptothecins. We previously used
our ex vivo familial genetics model to study mechanisms of camptothecin-induced
cytotoxicity.2 The goal of this study was identify regions of the genome which were
correlated to class-specific cytotoxicity and shared mechanisms of action.
The sensitivity of the CEPH cell lines to the indenoisoquinolines and the camptothecins was
evaluated using a growth inhibitory assay. Percent growth inhibition at the population mean
GI50 for each cell line was used to compare each compound. Interindividual variation in
response to the indenoisoquinolines was found to be positively correlated (Supplemental
Table 2). An inverse correlation was noted when comparing the two structural classes. A
number of cell lines which were resistant to all camptothecins were sensitive to all
indenoisoquinolines and vice versa. These differences in cytotoxic activity suggest that
while they share the same molecular target, there may be subtle distinctions in the
biochemical cascade required for compound action (e.g. uptake mechanisms, metabolism,
and secondary molecular interactions). Pommier suggests that (a) the differential genomic
targeting of Top1 cleavage complexes by the camptothecins and indenoisoquinolines, (b) the
differences in chemical structure and chemical stability of the indenoisoquinolines compared
with camptothecins, and (c) the low cross-resistance to camptothecins based on compound
efflux and Top1 point mutations, make it likely that indenoisoquinolines will exhibit unique
clinical and molecular properties which distinguish them from the camptothecins (4). Even
with a shared mechanism of action, mutations may render a cell sensitive or resistant to
these distinct structural classes. For example, Antony et al. reported that human leukemic
cells which were resistant to the camptothecins as a result of a Top1 point mutation were
sensitive to Ind1 (6). Not only can mutations in genes shared between these two classes
change sensitivity, but this data suggest that there might be subtle distinctions in genes
critical for action between the two classes (Table 2).
Nonparametric linkage analysis was used to identify regions of the genome which are
specific to the general mechanism of Top1 inhibition, and distinct regions associated with
the compound-induced cytotoxicity of camptothecins and indenoisoquinolines. Permutation
testing was used to define empirical LOD score thresholds for significant and suggestive
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linkage for each compound-concentration combination on each chromosome. Seven of nine
QTLs which had previously been identified as shared among camptothecin analogues were
replicated in this study. Four of those QTLs were also replicated at the significant and/or
suggestive level in all indenoisoquinolines (chr 1, 5, 11, 16; Table 1). These QTLs are
considered specific to the general mechanism of Top1 inhibition, while QTLs in Table 2 are
considered specific to the indenoisoquinolines. Different DNA cleavage patterns, biological
activity within the CEPH, and unique QTLs patterns suggest some genes may be more
selectively targeted by one compound class than the other (2, 3). While Ind1, Ind2, and Ind3
depend on Top1 for cytotoxic effect, siRNA knockdown of Top1 (at 80-90% efficiency)
does not completely reverse growth inhibition which suggests additional targets (2, 6).
Moreover, Ind2 and Ind3 have weak activity against Top2 (2). It’s too early to begin making
hypotheses about what genes under those class-specific QTLs might be critical to the
activity of the indenoisoquinolines. Since the discovery that this class of compounds acts on
Top1 in 1998, our search of Pubmed reveals only 34 articles about the class. These articles
predominately involve studies to optimize Top1 binding and potency.
The identification of QTLs on chromosomes 6 and 20, which are specific to the
camptothecins, is also intriguing. Most exciting is the fact that maximum peak LOD scores
observed for the QTL on chromosome 20 are centered over Top1 at 56 cM. This is the
primary molecular target of both the camptothecins and the indenoisoquinolines. The
absence of this QTL in the indenoisoquinolines does not mean that Top1 is not the
molecular target of the indenoisoquinolines. Failure to find linkage in this region on
chromosome 20 for the indenoisoquinolines could mean there was little or no genetic
variation in the CEPH cell lines used in this study that could be correlated to the observed
variation in phenotype. While the camptothecins and indenoisoquinolines share the same
binding pocket on Top1, mutations in this pocket affect their activity differently. The
camptothecins require hydrogen bonds to Top1 residues Arg364, Asn722, and Asp533 (4, 5).
A mutation in any one of these residues confers resistance to the camptothecins. Conversely,
the indenoisoquinolines hydrogen bond with Arg364 alone and are only sensitive to
mutations in this Top1 amino acid residue (4). We have extensively reviewed other
candidate genes under the QTL for chromosome 20 in another manuscript and refer the
readers to that article (9).
Gene ontology terms which are enriched for genes within the QTLs on chromosome 6 were
identified using the functional annotation clustering tool from (DAVID). The most
overrepresented GO terms for genes under the QTL on chromosome 6 at 0-29 cM were cell
differentiation (subcategory GO terms: apoptosis and cell death), protease inhibition, cell
proliferation, and regulation of biological processes (subcategory GO terms: transcription,
gene expression, DNA binding). Of the genes associated with these GO terms, there have
been reports for the involvement of both WRN and FOXQ1 in camptothecin-induced
cytotoxicity (1, 2). The QTL on chromosome 6 from 42-65 cM is enriched with genes
associated with chromatin assembly, response to chemical stimulus, and NF-kappa binding.
NF-kappa B interferes with the effect of most anti-cancer drugs through induction of anti-
apoptotic genes. Blocking NF-kappa B activation sensitizes cells to camptothecin analogues
(3). NF-kappa B tumor expression has been negatively correlated with response to irinotecan
(4). A number of genes involved in the NF-kappa B signaling pathway are present in this
QTL. This QTL also contains 22 members of the histone H1 family. The histones are
proteins which package and order DNA into nucleosomes. Phosphorylation of histone
H2AX is an extremely sensitive marker for double strand breaks induced by DNA damaging
agents, such as the camptothecins and indenoisoquinolines (5, 6). It has been suggested that
other histones are involved in DNA repair and cell proliferation (7). Studies indicate that
histones are ADP-ribosylated in vivo in response to DNA damage (8). All core histones,
including H1, can be mono-ADP ribosylated (7).
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Although the CEPH LCLs have been shown to be a reasonable model for studying genes
critical to drug action, the model is not without its limitations. This is an in vitro system was
intended to simplify response to drug therapy by cancer patients in a clinical setting. As
such, there are some pharmacokinetic and pharmacodynamic variables which cannot be
captured by the model that impact patient response. Additionally, confounders specific to in
vitro phenotyping, such as cellular growth rate, can affect cytotoxic response to anticancer
agents in LCLs (23).
We have characterized a method for clarifying the mechanism of action for Top1 inhibition
associated with the camptothecins and indenoisoquinolines. More than 25 years of research
have been devoted to identifying the molecular pathways associated with camptothecin-
induced cytotoxicity. Regions of the genome which contain known and potentially novel
genes critical to their action have identified and validated. The QTL on chromosome 20 as
well as those QTLs which are shared by both the indenoisoquinolines and camptothecins
(Table 1) are considered the most important for followup. QTLs related to the general
mechanism of Top1 inhibition may not only lead to predictions about camptothecin
sensitivity and resistance in patient populations but could provide valuable insight into
proposed functions of mammalian Top1 (24). We are currently performing ex vivo genome-
wide association studies, using lymphoblastoid cell lines from large numbers of unrelated
individuals. This will provide an approach to further investigate genetic influence on
cytotoxic response to a large panel of anticancer agents including the Topoisomerase 1
inhibitors. This association approach will allow us to significantly narrow down the broad
QTLs identified for the camptothecins and begin to identify genes critical to response.
Finally, genes under these QTLs which are identified through association studies could be
evaluated for their effect on camptothecin (and indenoisoquinoline) cytotoxicity using
shRNA gene knockdown experiments. These steps would increase the knowledge base
surrounding the molecular consequences of Top1 inhibition.
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Refer to Web version on PubMed Central for supplementary material.
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Concentration–response curve for (A) Ind1, (B) Ind2, and (C) Ind3. Data points represent
the overall population mean (n=142) for growth inhibition relative to untreated controls at
each concentration. Vertical bars represent the standard deviation for growth inhibition
across the population.
Watson et al. Page 11

























Watson et al. Page 12
Table 1
QTLs found in camptothecins and indenoisoquinolines
Chromosome Peak Start (cM) Peak End (cM) LOD† LOD§
1* 229 252 1.855 1.177
5* 125 194 1.709 1.551
6 0 29 1.528 -
6 42 65 1.652 -
11* 115 131 1.352 2.421
16* 0 75 1.345 2.139
20 42 101 2.134 -
*
QTLs which were also shared by the indenoisoquinolines
†
Maximum LOD score observed in this region associated with the camptothecins
§
Maximum LOD score observed in this region associated with the indenoisoquinolines
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Table 2
QTLs shared by all indenoisoquinolines
Chromosome Peak Start (cM) Peak End (cM) LOD*
2 1 34 2.024
4 192 211 1.483
6 100 192 2.286
10 118 155 1.775
13 67 114 1.44
16 27 108 2.139
18 0 31 1.574
18 90 96 1.554
*
Maximum LOD score observed in this region
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